Kyverna Therapeutics(US:KYTX)2026-03-26 20:06Financial Information - Kyverna Therapeutics, Inc. announced preliminary financial information for the year ended December 31, 2025, which is unaudited and subject to adjustments[6]. - The financial information provided is based on the company's current expectations and may be adjusted following year-end closing procedures[6]. Executive Appointment - Christi Shaw was appointed as Executive Chairperson of the Board, effective January 12, 2026[8]. - Ms. Shaw's initial annualized salary is set at $400,000, with additional equity awards including options for 185,000 shares and restricted stock units for 30,000 shares, both vesting over four years[10]. - If a "Change in Control" occurs during Ms. Shaw's employment, she will receive full acceleration of vesting for all unvested equity awards[12]. Corporate Information - The company is classified as an emerging growth company under the Securities Act of 1933[5]. - The press release detailing the corporate update and strategic priorities for 2026 was issued on January 12, 2026[6]. - The company is headquartered in Emeryville, California, with a principal executive office located at 5980 Horton St., Suite 550[2]. - The company trades on The Nasdaq Stock Market under the symbol KYTX[5]. Equity Awards - The performance restricted stock units (PRSUs) will vest upon the company's common stock reaching certain price targets, with a value of $200,000 divided by the per share Fair Market Value at the date of grant[10].